CN1052405C - Anti-cancer medicine and preparation method thereof - Google Patents
Anti-cancer medicine and preparation method thereof Download PDFInfo
- Publication number
- CN1052405C CN1052405C CN93100881A CN93100881A CN1052405C CN 1052405 C CN1052405 C CN 1052405C CN 93100881 A CN93100881 A CN 93100881A CN 93100881 A CN93100881 A CN 93100881A CN 1052405 C CN1052405 C CN 1052405C
- Authority
- CN
- China
- Prior art keywords
- sophoridine
- extraction
- preparation
- medicine
- foxtail
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a new anticancer medicine and a preparation method thereof, which is characterized in that sophoridine extracted from a traditional Chinese medicine, namely foxtail-like sophora seed, is used as an active constituent and is mixed with medicinal carriers and additives to prepare injections, tablets, capsules and other preparations. A preparation method of the new anticancer medicine comprises the following steps: taking the overground part of the foxtail-like sophora seed to obtain sophoridine through soak, percolation, ion exchange, alkalization, elution, primary salt transformation, dissociation, extraction, secondary salt transformation, dissociation, extraction, third salt transformation, dissociation, extraction, macrocrystalline and refining; adding hydrochloric acid to prepare injections; adding excipient to prepare tablets, capsules, etc. The anticancer medicine prepared by the preparation method has an obvious and stable anticancer effect on chorioepithelioma, chorioadenoma, lung cancer and digestive tract cancer, and has low toxic or side reaction. In addition, the resources of the foxtail-like sophora seed is abundant; the anticancer medicine has high content of sophoridine and low extractive cost, and is a new anticancer medicine with great value.
Description
The present invention relates to the new purposes of sophoridine.
Tumor is present world the world of medicine difficult problem anxious to be captured.Anticancer chemotherapy poison of drug and the side effect of using now is big, how to find that the higher and lower PTS of toxicity of curative effect is people's exigences.From natural product, from Chinese herbal medicine, obtain active anticancer component, be important directions and the approach of seeking PTS now in the world.
Contain multiple alkaloid in the Chinese medicine Herba Sophorae alopecuroidis, isolated 27 kinds of sophoridine, matrine, sophocarpine etc. so far.1972, the good equality of the island of Japan found that matrine wherein has active anticancer (" Medical Biology " Japanese 1972 84,65 phases) to animal-transplanted tumor.1984, people such as LI XUEMEI reported that sophocarpine has inhibitory action to animal tumor.But these several alkaloidal active anticancers are lower, and the content in Herba Sophorae alopecuroidis is also low, the extraction cost height.
The objective of the invention is to provide a kind of new purposes of sophoridine, its active anticancer is high and to produce cost lower.
The objective of the invention is such realization: the purposes of sophoridine in the medicine of preparation treatment people's pulmonary carcinoma and digestive tract cancer, it is characterized in that, the sophoridine that will extract from the Chinese medicine Herba Sophorae alopecuroidis mixes with pharmaceutical carrier and additive as active ingredient, make injection, tablet, capsule, be used for the treatment of people's pulmonary carcinoma and digestive tract cancer.
The preparation method of described sophoridine comprises the steps:
(1) get the Herba Sophorae alopecuroidis aerial parts, pulverize and be coarse powder, moistening with 1% sulfuric acid solution, soaked diafiltration routinely, the inventory of collecting 11 times of percolates 12 hours.
(2) ion exchange, alkalization, eluting, once change salt.
Percolate is filtered, and filtrate is adsorbed by styrene sulfonic acid h type resin post, gets saturated resin, resin is washed till colourless with distilled water, bleed off water, continue, put clean alkali liquor with 8% soaking with sodium hydroxide 4 hours, the alkali liquor methylbenzene extraction, resin merges with 70 ℃ of eluting of toluene, extract and eluent, again through 10% sulphuric acid extraction, promptly once change salt 10% sulphuric acid extraction, promptly once change salt;
(3) free, extraction, secondary change salt
Getting once changes the total alkali of salt saline solution, adds concentrated sodium hydroxide and transfers to pH11～12, and with the toluene extraction, toluene extract (mobile phase) carries out extraction separation through 5% hydrochloric acid (immobile phase) with countercurrent distribution, obtains the alkaloid neutralizer through thin layer chromatography evaluation, merging;
(4) free, extraction, No. three rotating disks.
Get the alkaloid neutralizer, it is free to add concentrated sodium hydroxide, with 60～90 ℃ of Petroleum ether extraction aloperines (otherwise processed), alkali liquor methylbenzene extraction then, methylbenzene extraction liquid separates through countercurrent distribution, promptly change salt (with 5% hydrochloric acid is immobile phase, and toluene is mobile phase) alkaloid neutralizer again for three times;
(5) free, extraction, coarse crystallization
Get the alkaloid neutralizer, it is free to add concentrated sodium hydroxide, and alkali liquor discards, and educt adds anhydrous sodium sulfate dehydration with 60～90 ℃ of petroleum ether extractiones of oily, adds the neutral alumina decolouring, reclaims small size, and cooling makes it crystallization, and the mother solution branch draws the sophoridine of coarse crystallization.
(6) dissolving, dehydration, decolouring, sucking filtration, refining
Get the sophoridine coarse crystallization, use 30-60 ℃ of petroleum ether dissolution, add and anhydrous sodium sulfate dehydration, the neutral alumina decolouring, the buchner funnel sucking filtration reclaims filtrate to small size, and cooling makes its crystallization, and mother solution is told, and gets the pure crystallization of sophoridine.Yield 0.45%.
(7) get sophoridine 12.5 gram and add about 600 milliliters of injection water, stirring and dissolving adds the hydrochloric acid solution (1 More/liter) of amount of calculation gradually, adds injection and is diluted with water to 1000 milliliters, stir evenly, filter to solution clarification, fill, sealing by fusing was sterilized 30 minutes, and system is carried injection.
The present invention can also make oral and capsule, and its method is as follows:
Make the method for oral tablet:
Get sophoridine 25 grams, add mixed with excipients, be pressed into tablet, every contains 25 milligrams of sophoridine.
Make capsular method:
Get sophoridine 25 grams, add mixed with excipients, incapsulate, every capsule contains 25 milligrams of sophoridine.
Anticancer pharmacology medicineization and clinical experiment that the present invention makes are as follows:
(1) to the anticancer experiment of animal
1, to the curative effect (in vivo test) of animal-transplanted tumor:
Laboratory animal hybrid and mouse inbred lines C57BL/6, DBA, 615, and animal tumor strain mice LLC, U14, S180, EAC, leukemia L1210, L615 are provided by Shanghai Pharmaceutical Inst., Chinese Academy of Sciences or Chinese Academy of Medical Sciences's institute.
Anticancer experiment reaches 1989 Nanning conference methods and carries out according to " national screening anticancer medicine rules " (1978), establishes 10,15,20mg/kg (30,45, and high, normal, basic three dosage of 60mg/m2 (ip, ig).
To mouse entity tumor lewis pulmonary carcinoma (LLC), U14, the cancer suppressing ratio of S180 etc. are 30-60% (P ∠ 0.05-0.01), the show dose relation.Increase in life span to ehrlich carcinoma EC oral administration is 25-50% (P＜0.05), is 26-38% (P＜0.05) to the increase in life span of S-180 (A).But it is invalid to L1210.In used tumor spectrum, better to the effect of solid tumor, wherein better with LLC car U14 effect.
Compare with known anticarcinogen cyclophosphamide, body weight does not descend in the sophoridine administration process, and animal is not dead, toxicity low (see Table 1, table 2)
Compare with matrine, oxymatrine in the Herba Sophorae alopecuroidis, consumption is few and cancer suppressing ratio is high.(table 3)
2, to EC cancerous cell concentration, sum, the influence of doubling time
Ip in mice EC 1 * 10
724h divides matched group and administration group, ip * 8d at random behind/the 0.2ml.
The result: 0-3d cancerous cell quantity is the growth of index sample behind the inoculation cancerous cell, and growth curve gradually departs from logarithm value behind the 3d; The 4-7d doubling time is: sophoridine 53h, and sophocarpine 59h, cyclophosphamide 70h, and matched group is 36h: extract d3 cancerous cell liquid counting cancerous cell concentration, sum obviously reduces, and the cancerous cell caryomitosis descends.Above presentation of results sophoridine has inhibitory action to EC.
3, external to cancerous cell killing experiments (trypan blue staining)
Sophoridine dilution back adds 3 * 10/0.1mlEAC ascites cells, puts in 37 ℃ of water-baths and hatches, and counting cancerous cell indigo plant is dyed rate.The result proves: the indigo plant of the sophoridine group rate of dying increases with drug level and prolongs action time and increases, and cancerous cell enlargement distortion, karyopyknosis, dissolving, even disappear alleviate but change with the drug level reduction.
4, to the influence of animal-transplanted tumor and normal structure amplifying nucleic acid content
(1) sophoridine influences administration behind 40 inoculations of mice oncocyte 24h to mice U14 and S180 tumor tissues and normal mouse spleen tissue core acid content, press literature method and extracts nucleic acid, press diphenylamines method survey RNA, orcin method survey DNA.The result proves that spleen tissue core acid content: RNA descends 36% behind the normal mouse ig sophoridine, and DNA descends 19%; S180 and U14 be tumor tissues nucleic acid suppression ratio U14 after the sophoridine treatment, DNA28.4%, RNA14.1%; S180DNA50.8%, RNA55.6%, only take temperature from containing (P＞0.05), and sophoridine is not obvious to the nucleic acid metabolism influence.
(2) micro-spectral degree method is measured the influence of sophoridine to oncocyte DNA
EAC, the S-180 of treatment, with the content decline 26.6-40% (P＞0.05) of U14 oncocyte DNA, the oncocyte nuclear fluorescence is dim before the treatment, karyon is more loose, nuclear morphology is irregular slightly.
(2) clinical experiment
With this anticancer drug therapy malignant trophoblastic disease (choriocarcinoma malignant mole) 20 examples certain curative effect is arranged through Jiangxi Province's health care of women institute.In 20 examples, clinical cure 15 examples, effective 3 examples, invalid 2 examples, total effective percentage reaches 90% (seeing Table 4).Not because of side effect drug withdrawal and bad complication, most patient appetite increases after the medication among the 20 routine patients.
Also effective in cure and have no side effect to pulmonary carcinoma and digestive tract tumor.
6, general pharmacology experiment:
Show that through zoopery and clinical trial this anticarcinogen does not all have tangible influence to nervous system, blood pressure, heart rate, electrocardiogram, breathing and the body's immunological function of animal.
7, toxicological experiment;
Show that through mutagenicity test and tertogenicity test this anticarcinogen does not have mutagenesis and teratogenesis.
Show that in vivo toxicity is low and do not have the savings phenomenon through acute toxicity test and long term toxicity test and clinic trial result.
More than experiment shows that the anticarcinogen that the present invention makes has active anticancer to multiple animal-transplanted tumor, clinical choriocarcinoma malignant mole, pulmonary carcinoma, digestive tract cancer antitumaous effect is obviously stablized.Its toxicity is low, does not reduce the body cell immunologic function, and no mutagenesis and do not have teratogenesis does not have the phenomenon of accumulating in vivo, with clinical anticancer chemotherapeutic agent commonly used at present tangible advantage is arranged relatively.The Herba Sophorae alopecuroidis resource is very abundant.Sophoridine is the alkaloid that wherein content is the highest (0.45%), and than matrine, sophocarpine height, it is lower that anticancer effective dose then is lower than matrine, sophocarpine, extraction cost, is a kind of of great value PTS.
Table 1 sophoridine is to effect P＞0.05 ★ P＞0.05 ★ ★ P＜0.01 of solid tumor ● X ± SD
| Tumor | Approach | Dosage | Mice | Body weight (g) | Tumor is heavy | Cancer suppressing ratio (%) | ||
| mg/kg×d | Before | After | Before | After | (g) | |||
| Cervical cancer 14 (mice) | ip ip ip ip | control Endoxan 20×10 20×10 15×10 10×10 | 10 10 10 10 10 | 10 8 10 10 10 | 20.5±2.0 20.8±0.92 20.3±1.3 20.0±1.3 20.0±2.0 | 20.0±3.0 17.8±1.0 21.5±1.60 22.4±1.80 19.5±3.80 | 1.76±0.30 0.69±0.16 0.70±0.14 0.85±0.20 1.2±0.30 | 60● 60● 52● 32★★ |
| ip ip ip ip | Control Endoxan 20×10 20×10 15×10 10×10 | 12 10 10 10 10 | 12 8 10 10 10 | 22.1±1.6 22.0±1.5 22.1±1.9 21.7±1.3 22.0±1.5 | 23.5±1.3 17.5±0.9 23.6±1.9 23.4±0.1 23.5±1.0 | 1.58±0.3 0.63±0.2 0.62±0.1 0.79±0.1 1.10±0.2 | 60.3● 60.0● 50.0● 30★★ | |
| ip ip ip | control 10×10 15×10 20×10 | 12 10 8 10 | 12 10 8 10 | 22.0±1.0 21.8±0.7 21.7±0.9 21.8±1.8 | 22.0±0.5 19.6±0.2 21.0±1.2 23.0±1.3 | 1.8±0.2 1.2±0.2 0.9±0.2 0.8±0.3 | 35★★ 48● 56● | |
| ig ig ig | Control 20×10 15×10 10×10 | 10 10 10 8 | 10 10 10 8 | 20.4±1.1 19.9±1.7 20.6±1.8 20.4±1.7 | 19.0±1.1 20.3±1.7 20.7±1.8 18.0±2.3 | 1.90±0.60 0.73±0.14 0.96±0.28 1.1±0.60 | 61.5● 50● 43★★ | |
Continuous table 1
| Sarcoma 180 (mice) | ip ip ip ip | Control Endoxan 20×11 20×11 15×11 10×11 | 10 10 10 10 10 | 10 8 10 10 10 | 19.6±1.1 20.8±1.0 19.6±1.1 20.0±1.2 20.3±1.2 | 21.0±2.5 18±1.6 20±3.0 20.5±2.9 19±4 | 2.00±0.40 0.70±0.17 1.20±0.4 1.3±0.30 1.4±0.20 | 64.4● 41● 35★★ 30★★ |
| ig | Eontrol 20×10 | 0 0 | 9 8 | 20.7±1.1 20.0±1.4 | 19.7±2.4 19.6±0.21 | 1.60±0.06 0.34±0.07 | 41● | |
| ip ip ip ip | Control Endoxan 20×11 20×11 15×11 10×11 | 10 10 10 10 10 | 10 18 10 10 10 | 20.7±1.4 20.8±0.6 21.0±1.3 20.2±1.2 20.0±1.7 | 21.0±1.9 18±1.0 20±1.8 20.1±2.3 20.7±1.6 | 2.10±0.80 0.60±0.10 0.90±0.6 1.3±0.40 1.4±0.30 | 63.2● 55.5● 37.8★★ 34★★ | |
| ip ip ip | Control 20×7 15×7 10×7 | 10 10 10 10 | 10 10 10 10 | 19.1±1.3 19.1±1.2 19.0±2.5 19.2±1.5 | 22.1±1.4 22.5±1.9 20.2±2.0 21.0±1.1 | 1.70±0.50 0.97±0.20 1.1±0.20 1.2±0.30 | 42.6● 34.9★★ 28.9★ | |
| Lewis lung cancer (mice) | ip ip ip | control 20×10 15×10 10×10 | 10 10 10 10 | 10 9 10 10 | 21.0±2.0 21±2 21.0±1.7 20.6±1.8 | 20.0±0.97 20±3 21±3 20.0±1.8 | 1.9±0.8 0.87±0.07 0.93±0.05 1.3±0.80 | 58● 51★★ 31★★ |
| ig ig ig | Control 20×10 10×10 5×10 | 10 10 8 10 | 10 10 0 10 | 20.2±1.5 20.4±1.5 20.4±1.8 20.4±1.5 | 18.0±0.1 19.0±1.4 17.5±1.1 18.0±1.3 | 2.5±1.1 1.5±0.76 1.6±0.82 1.75±0.62 | 40● 37★★ 30★★ |
Table 2 sophoridine is to ascites tumor and leukemic effect X ± SD P＞0.05 ★ P＜0.05 ★ ★
| Tumor | Approach | Dosage | Mice | Body weight (g) | Life span (day) | Increase in life span (%) | ||
| (mg/kg×d) | Before | After | Before | After | ||||
| Ehrlich ascites tumor (mice) | ip ip ig | control 10×5 Control 10×8 20×8 | 10 10 10 10 10 | 0 0 0 0 0 | 20.0±1.3 20±1.4 20.0±1.3 20.0±1.6 20.0±1.4 | 29.0±3.0 24.1±0.5 28.8±3 25.8±3.0 26.6±2.4 | 16±0.80 24±0.07 16.2±4.4 19.7±3.6 21.2±4.1 | 50★★ 25★ 31★★ |
| Sarcoma 180 (mice) | ig ip ip | control 20×8 Control 10×8 20×8 | 10 10 10 10 10 | 0 0 0 0 0 | 19.3±2.3 18.9±2.4 22.4±2.5 20.0±1.5 20.0±0.7 | 23.3±2.5 21.6±2.7 26.0±1.1 25.0±2.5 26.0±4.0 | 15±4 19±6 16±4 17±4 22±10 | 26★ 6★ 38★★ |
| Leukemia 1210 (mice) | ig | control 20×10 | 10 10 | 0 0 | 17.8±2.1 18.3±1.1 | 17.8±1.6 17.8±2.0 | 8.7±1.2 7.4±1.4 | 18★ |
Various alkaloids are to antitumaous effect ip X ± SD p＞0.05 ★ p＜0.05 ★ ★ p＜0.01 of S-180 in the table 3 comparison Herba Sophorae alopecuroidis ●
| Title and formal name used at school | Dosage sky mg kg days | Number of animals | Body weight (g) | Tumor heavy (gram) | Cancer suppressing ratio (%) | ||
| Beginning | Eventually | Beginning | Eventually | ||||
| Blank 5Fu sophoridine matrine oxymatrine | Control group 15 * 10 20 * 10 10 * 10 50 * 10 25 * 10 50 * 10 25 * 10 | 12 10 10 10 10 10 10 10 | 12 9 10 10 9 10 10 10 | 19±1.1 19.5±1.0 10.9±1.7 19.2±1.3 19.8±2.1 20±2.4 20±1.67 20±1.5 | 19.6±2.1 19±1.1 19±1.0 19.3±1.5 20.1±1.4 21±2.7 20±3.1 20±3.0 | 1.8±0.64 0.9±0.10 1.01±0.46 1.2±0.30 1.18±0.43 1.45±0.69 1.21±0.6 1.4±0.3 | 50● 43.8● 33.3★★ 34.4★★ 19.4★ 32.7★★ 22★ |
| Blank 5Fu sophoridine matrine oxymatrine | Matched group 15 * 7 20 * 7 50 * 7 50 * 7 | 12 10 10 10 10 | 12 10 10 9 9 | 19±1.3 19.2±1.0 19.9±1.5 19.6±1.6 19±1.6 | 21.5±2 19±0.8 22±1.6 18.5±2.1 19.5±1.6 | 1.69±0.5 0.9±0.1 1.0±0.2 0.96±0.34 1.04±0.33 | 46.7● 40.8● 43.2★★ 38.5★★ |
| Blank 5Fu sophoridine oxymatrine matrine | Matched group 15 * 8 20 * 8 50 * 8 50 * 8 | 12 10 10 10 10 | 12 9 10 9 10 | 22.7±1.7 22±1.8 22±1.0 22±2.1 22.4±1.7 | 22±2.1 21.4±1.8 22.3±1.4 24±3.4 22.9±1.7 | 1.48±0.39 0.8±0.1 0.73±0.1 1.22±0.48 1.16±0.5 | 45.9● 50● 17★ 21.6★ |
Table 4 clinical stages and curative effect
| The tumor example is planted number | Clinical stages | ||||||||||||||||||||
| I | II | III | VI | Add up to | |||||||||||||||||
| A B | A B | ||||||||||||||||||||
| Recovery from illness | Effectively | Invalid | Recovery from illness | Effectively | Invalid | Recovery from illness | Effectively | Invalid | Recovery from illness | Effectively | Invalid | Recovery from illness | Effectively | Invalid | Recovery from illness | Effectively | Invalid | Recovery from illness | Effectively | Invalid | |
| Malignant tumor 17 | 1 | 4 | 1 | 5 | 3 | 2 | 1 | 13 | 3 | 1 | |||||||||||
| Floss tumor 3 | 1 | 1 | 1 | 2 | 1 | ||||||||||||||||
| Add up to 20 | 1 | 4 | 1 | 1 | 6 | 4 | 2 | 1 | 15 | 3 | 2 | ||||||||||
Claims (1)
1, the purposes of sophoridine in the medicine of preparation treatment people's pulmonary carcinoma and digestive tract cancer, it is characterized in that, the sophoridine that will extract from the Chinese medicine Herba Sophorae alopecuroidis mixes with pharmaceutical carrier and additive as active ingredient, makes injection, oral tablet and capsule, is used for the treatment of people's pulmonary carcinoma and digestive tract cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93100881A CN1052405C (en) | 1993-01-18 | 1993-01-18 | Anti-cancer medicine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93100881A CN1052405C (en) | 1993-01-18 | 1993-01-18 | Anti-cancer medicine and preparation method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99124918 Division CN1295076A (en) | 1999-12-01 | 1999-12-01 | Sophorine extracting process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1089846A CN1089846A (en) | 1994-07-27 |
| CN1052405C true CN1052405C (en) | 2000-05-17 |
Family
ID=4983284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93100881A Expired - Fee Related CN1052405C (en) | 1993-01-18 | 1993-01-18 | Anti-cancer medicine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1052405C (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110339C (en) * | 2000-06-19 | 2003-06-04 | 宁夏药物研究所 | Process for preparing total allooerine liquid |
| CN1325495C (en) * | 2000-11-18 | 2007-07-11 | 宁夏药物研究所（有限公司） | Preparation process of sophoridine |
| CN1325496C (en) * | 2000-11-18 | 2007-07-11 | 宁夏药物研究所（有限公司） | Preparation process of sophora alopecuroides series alkaloid salts substances |
| CN1111532C (en) * | 2000-11-25 | 2003-06-18 | 宁夏药物研究所 | The preparation technology of sophocarpine |
| CN1211083C (en) * | 2001-06-14 | 2005-07-20 | 通化方大药业股份有限公司 | Sophoridine and its application in analgesic |
| CA2521123A1 (en) * | 2003-04-03 | 2004-10-14 | Hsun-Lang Chang | Composition and method for supporting cancer treatments |
| CN100335075C (en) * | 2004-01-02 | 2007-09-05 | 中国科学院新疆理化技术研究所 | Method for extracting effective component from sophora alopecuroide for reducing blood fat and its medicinal use |
| CN100390171C (en) * | 2004-02-10 | 2008-05-28 | 上海佳谷药业有限公司 | Method for extracting dophoridine from residual solution of matrine extracting solution from fenugreek |
| CN1305471C (en) * | 2005-04-20 | 2007-03-21 | 刘平 | Use of sophoridine oxide in preparing anticancer medicine |
| CN102659784A (en) * | 2012-05-11 | 2012-09-12 | 宁夏紫荆花制药有限公司 | Method for preparing high-purity aloperine |
| US9518211B2 (en) * | 2013-01-25 | 2016-12-13 | Basf Se | Method for recovering oil |
| CN106389546A (en) * | 2016-10-18 | 2017-02-15 | 漯河医学高等专科学校 | Traditional Chinese medicine for postoperative treatment of colorectal cancer and preparation method of traditional Chinese medicine |
| CN107021970A (en) * | 2017-03-21 | 2017-08-08 | 南方医科大学 | Sophora alopecuroide alkali dimer A~applications of the D in anti-inflammatory or anti-tumor medicinal preparation is prepared |
| CN113288896A (en) * | 2021-05-28 | 2021-08-24 | 成都中医药大学 | Application of sophoridine in preparation of anti-herpes virus medicine |
-
1993
- 1993-01-18 CN CN93100881A patent/CN1052405C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 《中国药理学报》8卷2期 1987.3.1 李雪梅等 槐定的抗癌作用 * |
| 《中药化学》第1版 1987.11.1 肖崇厚等上海科学技术出版社 * |
| 《中药化学》第1版 1987.11.1 肖崇厚等上海科学技术出版社;《中国药理学报》8卷2期 1987.3.1 李雪梅等 槐定的抗癌作用 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1089846A (en) | 1994-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1052405C (en) | Anti-cancer medicine and preparation method thereof | |
| CN101554409B (en) | Long pepper alkaloid and preparation method, preparation and application thereof | |
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN103340983A (en) | Lycium ruthenicum fruit extract as well as preparation method and application thereof | |
| CN101306077B (en) | Chinese traditional injection preparation for treating cancer and its preparation method | |
| CN112472729A (en) | Application of caulis sinomenii in preparing medicine for treating human glioma | |
| EP0416502A1 (en) | A pharmaceutical composition having antitumor activity and preparation for its manufacture | |
| CN1706397A (en) | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte | |
| CN101537036A (en) | Soap pod saponin extract as well as preparation method and application thereof | |
| CN1883566A (en) | Anti-inflammation medicine and method for preparing same | |
| CN1295076A (en) | Sophorine extracting process | |
| CN101396373B (en) | Cinobufacini extract and preparation method thereof | |
| CN1939396A (en) | Suberect spatholobus stem extract with antineoplastic function and its making method | |
| CN1274684C (en) | Bee glue flavone extract preparation method, pharmaceutical preparation and its new medical uses | |
| CN1438237A (en) | Echinocystic acid preparation, medicinal preparation and new use as medicine | |
| CN100584345C (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, extraction method and application | |
| CN100482266C (en) | Medical composite prepared by sarcandra and oldenlandia | |
| CN107485615A (en) | Purposes of the Ligustrum robust glycosides C and combinations thereof in treatment hyperlipidemia and slimming medicine is prepared | |
| CN1911272A (en) | Powder injection contg. high content tanshin polyphenolic acid salts, and its prepn. method | |
| CN102070700A (en) | Marsdenia tenacissima saponins H and preparation method and application thereof | |
| CN1961894B (en) | A novel compound pharmaceutical composition, preparation method and use thereof | |
| CN1171896C (en) | Syringic general saponin extractive and its prepn and medicinal composition | |
| CN1850837A (en) | 9-(1,3-benzo dioxolyl-5_)-4-(beta-D-glucopyranosyloxy)-6,7-dimethoxy naphthale [2,3-C] furna-1(3II] ketone, and its preparing method and medicinal composition containing same | |
| CN101011543A (en) | Antineoplastic medicine composition | |
| CN1476839A (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |